- Select a blog category
by Karen Taylor
Earlier this week I presented the key findings from our February 2017 report, Time to care: Securing a future for the hospital workforce in the UK, at a breakfast meeting at Northern Ireland’s NHS Confederation (NICON) conference highlighting the hospital workforce challenges and potential solutions for hospitals in the UK. In discussing our findings with an engaged audience, a particularly emotive issue was highlighted – the challenges facing our older and more experienced members of staff. Our research suggests that introducing more flexible working and addressing some of the hygiene factors identified in our report could help address this problem. I therefore thought I would use this week’s blog to explore this issue in more detail.
by Greg Reh
Blockchain technology is continually touted to revolutionise the operations of every industry it becomes associated with, and for health care and life sciences this no different. This week’s blog, by Greg Reh, Deloitte’s Global Life Sciences and Health Care Leader, discusses the possible use cases blockchain may have in health care. The blog first appeared in on the US Center for Health Solutions website, part of their My Take series.i
by Pratik Avhad
India is one of the leading global producers of low-cost generic medicines due to its high domestic demand and inexpensive manufacturing costs. The country’s pharmaceutical market is the world’s third largest in terms of volume, but the thirteenth largest in value.1 However, counterfeiting is pervasive, with an estimated 20 per cent ($4.3 billion in 2013-14) of India’s drug market comprised of counterfeit drugs.2,3 While counterfeiting is a global issue, it is much more prevalent in low and middle income countries with an estimated 10 to 30 per cent of medicines in these countries being counterfeit, compared to just one per cent of medicines in high-income countries.4
by Karen Taylor, Director, Centre for Health Solutions
In November 2017 we launched our report - ‘The future awakens: life sciences and health care predictions 2022’ - which provides an overview of six predictions that we believe will transform health care. This article, which first appeared in the Med Tech Innovation (MIT) news magazine,1 discusses the key medical technology innovations that I believe will impact health care in 2018.
by Anni Mekhail
The March 2018 Healthcare Information and Management Systems Society (HIMSS) annual conference in Las Vegas provided a wealth of insight into the products, investments, and innovations hitting the healthcare industry. The convention included over 1000 exhibitors, from global tech giants and health focussed incumbents, to numerous academic and research centres, healthcare investors, incubators, and start-up companies. As a doctor working in management consulting, I enjoyed my first experience of HIMSS and came away with some valuable ideas and insights, including my top five takeaways which I highlight below.
by Mark Steedman, PhD
This week is World Glaucoma Week, aimed at raising awareness around glaucoma – a group of eye diseases that lead to damage to the optic nerve and can cause permanent vision loss. World Glaucoma Week encourages people to have regular eye checks to detect glaucoma (and other eye diseases) early and pursue treatment to preserve their vision.1
By Terri Cooper, PhD, and Dr. Stephanie Allen
In our Predictions 2022 report, The future awakens, we highlight as one of our six predictions that ‘the culture in health care is being transformed by digital technologies’, with smart health care delivering more cost-effective patient-centred care through digitally-enabled hospitals. This week’s blog first appeared as a US Center for Health Solutions blog, A view from the Center. It discusses in more detail how rapidly-evolving technologies and growing consumerism, along with demographic and economic changes, are already disrupting hospitals and considers how several megatrends might impact how hospitals of the future are staffed, sized, and designed.
by Thomas Croisier and James Forsyth, Deloitte Consulting, LLP
This week’s blog is by Tomas Croisier and James Forsyth, a partner and director in our life sciences consulting practice, respectively. It was first featured in a blog post on the US Center of Health Solutions site, and explores the impact of biosimilars may have on the treatment of oncology, particularly in the US.1
On Monday 19th of February we launched the UK cut of our Time to care report at a jointly sponsored Cambridge Health Network event at the Deloitte offices here in London. Our UK report builds on our larger European study, launched last November, which examined the workforce challenges and actions needed to secure a sustainable clinical workforce for the future in 15 countries across Europe. Our UK report takes a deeper look at the research evidence collected for the European report, including the crowdsourced survey of hospital doctors and nurses. We supplemented the research with further interviews, data analysis, literature reviews and insights from Deloitte staff working with NHS and private sector clients across the four UK countries. Although we acknowledge the significant challenges currently facing the hospital and wider healthcare sector, we identify a huge amount of positivity and commitment from employers and staff and highlight 17 evidence based case examples of innovative approaches to tackling staff recruitment, retention and deployment.
The term ‘revolution’ is often used to define a popular uprising that can lead to dramatic political changes. A dictator is overthrown, a new government is formed, a constitution is changed or replaced, and immeasurable impact on the country or even the world can occur. However, other types of revolutions also happen. Some of the most commonly known are industrial revolutions, which refer to breakthroughs in technology that change how industries function. We are now seeing the beginnings of a fourth industrial revolution – a fusing of technologies blurring the boundaries between the physical, digital and biological worlds.1 This blog highlights the issues that Deloitte believe will cause the most disruption for life sciences in 2018 as we embark on this fourth industrial revolution.
Most people will have been impacted by cancer in some way – whether themselves, a family member, a loved one or an acquaintance. Stories about the causes of cancer and examples of exciting new breakthrough treatments feature regularly in media headlines. However, one issue more than any others attracts attention, and that’s evidence of inequalities in patient outcomes. Last week’s World Cancer Day, on 4th February, coincided with the publication of the CONCORD-3 report, comparing the outcomes for cancer patients from 73 different countries over the period 2000-2014.1 This week’s blog reflects on some of the developments in the UK given the results of this ground breaking research suggests that the UK continues to lag behind many other comparable European countries.